As an AI language model, I can provide information up until September 2021. However, please note that the top major drug approvals may vary depending on factors such as therapeutic area and commercial success. Here are ten notable drug approvals by the U.S. Food and Drug Administration (FDA) in 2021:
1. Aduhelm (aducanumab): Approved for Alzheimer’s disease treatment after controversial discussions.
2. Abecma (idecabtagene vicleucel): CAR-T cell therapy for relapsed or refractory multiple myeloma.
3. Rybrevant (amivantamab-vmjw): Targeted therapy for non-small cell lung cancer with EGFR exon 20 insertion mutations.
4. Lumakras (sotorasib): Approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
5. Padcev (enfortumab vedotin-ejfv): Used for advanced urothelial and bladder cancer.
6. Ponvory (ponesimod): Approved for relapsing forms of multiple sclerosis.
7. Byfavo (remimazolam): Short-acting sedation for procedures requiring anesthesia.
8. Cabenuva (cabotegravir and rilpivirine): Monthly injectable treatment for HIV.
9. Isturisa (osilodrostat): Used for Cushing’s disease treatment.
10. Roszet (ezetimibe and rosuvastatin): Combination tablet for high cholesterol treatment.
Please note that this is not an exhaustive list, and there may be other important drug approvals that occurred during the current year.